


Infobox drug

<! Monoclonal antibody data >

<! Clinical data >

<! Legal status >

<! Pharmacokinetic data >

<! Identifiers >

<! Chemical and physical data >


Frunevetmab sold under the brand name Solensia is a medication used to treat pain associated with osteoarthritis in cats

It is the first monoclonal antibody new animal drug approved by the US Food and Drug Administration (FDA) for use in any animal species

Frunevetmab is the international nonproprietary name (INN)

 Clinical usage 
Frunevetmab is a catspecific monoclonal antibody (a type of protein) designed to recognize and attach to a protein called nerve growth factor (NGF) that is involved in the regulation of pain When frunevetmab binds to NGF it prevents the pain signal from reaching the brain

Frunevetmab is Indication (medicine)
The most common side effects seen in cats include vomiting diarrhea injection site pain scabbing on the head and neck dermatitis and pruritus (itchy skin)

History
In February 2021 Frunevetmab was approved for medical use in the European Union

In January 2022 the following year Frunevetmab was approved for medical use in the United States

Development as a potential drug for humans was stopped due to risk concerns over worsening osteoarthritis 

See also
Monoclonal antibody

 References 



 Bibliography 
 

 External links 
 






